Ultima Markets: [Market hotspot] Weight loss and diabetes drugs are popular, Novonor...

丹麦制药公司Novo Nordisk诺和诺德 (NVO) 最近因其减重药Wegovy和糖尿病药物Ozempic的需求增加，上修其年度财务展望。这些药物是通过每周注射给予，并且因其显著的减重效果而受到患者的追捧。

诺和诺德上修财测

Novo Nordisk 表示，销售增长将在32%To38％之间，高于先前的27%To33％的估计。该公司还预计营业利润增长将达到40%To46％，高于先前的31%To37％的预测。乐观的展望主要是由于Ozempic在美国市场的销售超出预期。

诺和诺德股价创今年新高

WegovyandOzempic的受欢迎程度使Novo Nordisk成为欧洲最有价值的公司。该公司在美国上市的ADR股票也创下了今年的新高。 Novo NordiskWill be on11month2日公布其第三季度盈利。

NVOannounce13$100 million acquisition

Novo Nordisk将支付高达13亿美元予KBP Biosciences购买新药Ocurenone。 该药物可以帮助那些难以控制高血压的病人。购买新药的交易将在今年年底完成，并不会影响该公司今年的利润。

(Novo Nordisk ADR 年初至今表现)

Disclaimers

The comments, news, research, analysis, pricing, and other information contained in this article can only be considered as general market information and are provided solely to assist readers in understanding the market situation and do not constitute investment advice.Ultima MarketsReasonable measures have been taken to ensure the accuracy of the data, but the accuracy of the data cannot be guaranteed and can be changed at any time without notice.UltimaMarketsWe will not be responsible for any losses or losses (including but not limited to any loss of profits) that may arise from the direct or indirect use or reliance on such information.